Table 2.

Subgroup analysis of the pure efficacy of all antidepressants at week 8

All of drugs	Arms (sample size)	Efficacy at week 8, % (95% CI)	Corrected efficacy at week 8,% (95% CI)
Overall	355 (40 455)	10.3 (1.10~28.1)	9.44 (0.67~22.2)
Sample size
n < 250	133 (7567)	14.4 (2.92~34.4)	10.5 (0.98~24.0)
n ≥ 250	222 (32 888)	9.06 (0.92~18.8)	8.99 (0.70~18.8)
Trial design
Placebo run-in	208 (20 970)	10.4 (2.13~32.7)	9.75 (1.31~21.3)
Non placebo run-in	40 (5155)	10.4 (-0.01~29.8)	9.82 (-0.01~17.4)
Publication year
Before 2000	112 (8729)	15.7 (4.42~34.1)	12.0 (2.23~23.3)
After 2000 (2000 included)	156 (22 207)	9.52 (1.84~25.0)	9.43 (1.15~23.5)
Number of arms per trial
≤2	55 (5975)	13.2 (2.45~38.5)	10.3 (2.45~21.8)
≥3	300 (34 480)	9.68 (0.91~27.4)	9.33 (0.33~22.1)
Number of study sites
1	43 (1883)	16.7 (6.13~34.6)	10.1 (0.74~24.2)
>1	289 (37 242)	9.44 (0.86~22.1)	9.09 (0.63~20.4)
Funding source
Industry-sponsored	257 (29986)	9.87 (1.06~25.4)	9.15 (0.90~20.0)
Non industry-sponsored	85 (9184)	11.8 (2.40~27.9)	10.3 (-0.29~25.0)
Type of subject
Inpatients	21 (944)	21.7 (10.8~44.5)	8.89 (0.63~22.9)
Noninpatients	281 (31 830)	10.3 (1.02~25.7)	9.73 (0.82~21.2)
Type of scale
HAMD-17	166 (18 908)	9.43 (1.19~27.5)	8.72 (0.85~21.0)
Non HAMD-17	189 (21 547)	10.6 (1.17~28.1)	9.84 (0.51~23.7)
Dosing regimen
Fixed dose	181 (22 759)	9.23 (0.34~25.9)	8.89 (0.34~22.4)
Flexible dose	172 (17 671)	11.5 (1.30~30.7)	10.2 (1.05~21.8)
Mean age, y
<41	158 (17 540)	9.99 (0.51~21.5)	9.41 (-0.48~19.9)
≥41	167 (20 374)	10.63 (2.72~31.1)	9.61 (2.13~24.9)
Standardized baseline
<0.44	162 (17 018)	9.96 (0.59~25.6)	9.47 (0.59~21.1)
≥0.44	193 (23 437)	10.4 (2.12~33.7)	9.44 (1.49~23.2)
Females, %
<63%	94 (10 983)	11.0 (0.11~27.2)	8.83 (-0.03~23.5)
≥63%	106 (13 676)	9.38 (1.39~25.1)	8.92 (0.80~22.5)

Abbreviations: CI, confidence interval; HAMD, Hamilton Depression Rating Scale.